Treatment strategies for highly treatment-experienced HIV-infected patients.

about

Surveillance programs for detection and characterization of emergent pathogens and antimicrobial resistance: results from the Division of Infectious Diseases, UNIFESP.

P2860

Q37590197-4C8E626F-AAE4-4FBF-AD71-B911A1DEBDCA

P2860

Treatment strategies for highly treatment-experienced HIV-infected patients.

Item

http://www.wikidata.org/entity/Q36278090

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Treatment strategies for highly treatment-experienced HIV-infected patients.

@ast

Treatment strategies for highly treatment-experienced HIV-infected patients.

@en

type

Item

label

Treatment strategies for highly treatment-experienced HIV-infected patients.

@ast

Treatment strategies for highly treatment-experienced HIV-infected patients.

@en

prefLabel

Treatment strategies for highly treatment-experienced HIV-infected patients.

@ast

Treatment strategies for highly treatment-experienced HIV-infected patients.

@en

P1476

Treatment strategies for highly treatment-experienced HIV-infected patients.

@en

P2093

Andrew D Luber

http://www.w3.org/2001/XMLSchema#string

P2860

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.

In vitro antiviral interaction of lopinavir with other protease inhibitors.

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens.

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

P304

815-823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14787210.3.5.815

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16207173

http://www.w3.org/2001/XMLSchema#string

Treatment strategies for highly treatment-experienced HIV-infected patients.

about

P2860

P2860

Treatment strategies for highly treatment-experienced HIV-infected patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698